nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentazocine—EBP—Raloxifene—osteoporosis	0.298	0.699	CbGbCtD
Pentazocine—Dezocine—Estradiol—osteoporosis	0.261	0.563	CrCrCtD
Pentazocine—Levorphanol—Estradiol—osteoporosis	0.202	0.437	CrCrCtD
Pentazocine—SIGMAR1—Raloxifene—osteoporosis	0.128	0.3	CbGbCtD
Pentazocine—SIGMAR1—Levonorgestrel—Ethinyl Estradiol—osteoporosis	0.00148	1	CbGdCrCtD
Pentazocine—Loss of consciousness—Raloxifene—osteoporosis	0.000319	0.0034	CcSEcCtD
Pentazocine—Face oedema—Estradiol—osteoporosis	0.000318	0.00338	CcSEcCtD
Pentazocine—Paraesthesia—Etidronic acid—osteoporosis	0.000318	0.00338	CcSEcCtD
Pentazocine—Tinnitus—Risedronate—osteoporosis	0.000317	0.00338	CcSEcCtD
Pentazocine—Irritability—Estradiol—osteoporosis	0.000314	0.00334	CcSEcCtD
Pentazocine—Hypertension—Ibandronate—osteoporosis	0.000311	0.0033	CcSEcCtD
Pentazocine—Agranulocytosis—Zoledronate—osteoporosis	0.000307	0.00327	CcSEcCtD
Pentazocine—Anaphylactic shock—Estropipate—osteoporosis	0.000306	0.00326	CcSEcCtD
Pentazocine—Hypertension—Calcitriol—osteoporosis	0.000304	0.00323	CcSEcCtD
Pentazocine—Constipation—Etidronic acid—osteoporosis	0.000303	0.00322	CcSEcCtD
Pentazocine—Flushing—Pamidronate—osteoporosis	0.0003	0.0032	CcSEcCtD
Pentazocine—Dry mouth—Ibandronate—osteoporosis	0.000299	0.00319	CcSEcCtD
Pentazocine—Cramp muscle—Estradiol—osteoporosis	0.000297	0.00316	CcSEcCtD
Pentazocine—Anaphylactic shock—Ibandronate—osteoporosis	0.000294	0.00312	CcSEcCtD
Pentazocine—Dry mouth—Calcitriol—osteoporosis	0.000293	0.00312	CcSEcCtD
Pentazocine—Muscle spasms—Ethinyl Estradiol—osteoporosis	0.000292	0.00311	CcSEcCtD
Pentazocine—Shock—Raloxifene—osteoporosis	0.000292	0.0031	CcSEcCtD
Pentazocine—Feeling abnormal—Etidronic acid—osteoporosis	0.000292	0.0031	CcSEcCtD
Pentazocine—Chills—Pamidronate—osteoporosis	0.00029	0.00309	CcSEcCtD
Pentazocine—Shock—Ibandronate—osteoporosis	0.000289	0.00307	CcSEcCtD
Pentazocine—Anaphylactic shock—Calcitriol—osteoporosis	0.000287	0.00306	CcSEcCtD
Pentazocine—Hyperhidrosis—Raloxifene—osteoporosis	0.000287	0.00305	CcSEcCtD
Pentazocine—Muscle spasms—Risedronate—osteoporosis	0.000285	0.00303	CcSEcCtD
Pentazocine—Hyperhidrosis—Ibandronate—osteoporosis	0.000284	0.00302	CcSEcCtD
Pentazocine—Nausea—Ergocalciferol—osteoporosis	0.000283	0.00301	CcSEcCtD
Pentazocine—Sweating increased—Estradiol—osteoporosis	0.000277	0.00295	CcSEcCtD
Pentazocine—Insomnia—Estropipate—osteoporosis	0.000277	0.00295	CcSEcCtD
Pentazocine—Dysgeusia—Pamidronate—osteoporosis	0.000276	0.00294	CcSEcCtD
Pentazocine—Paraesthesia—Estropipate—osteoporosis	0.000275	0.00292	CcSEcCtD
Pentazocine—Flushing—Zoledronate—osteoporosis	0.000274	0.00292	CcSEcCtD
Pentazocine—Visual impairment—Conjugated Estrogens—osteoporosis	0.000274	0.00292	CcSEcCtD
Pentazocine—Anorexia—Calcitriol—osteoporosis	0.000274	0.00291	CcSEcCtD
Pentazocine—Abdominal discomfort—Estradiol—osteoporosis	0.000273	0.0029	CcSEcCtD
Pentazocine—Somnolence—Estropipate—osteoporosis	0.000272	0.0029	CcSEcCtD
Pentazocine—Muscle spasms—Pamidronate—osteoporosis	0.000271	0.00288	CcSEcCtD
Pentazocine—Erythema multiforme—Conjugated Estrogens—osteoporosis	0.000269	0.00286	CcSEcCtD
Pentazocine—Insomnia—Raloxifene—osteoporosis	0.000268	0.00285	CcSEcCtD
Pentazocine—Vertigo—Risedronate—osteoporosis	0.000266	0.00283	CcSEcCtD
Pentazocine—Syncope—Risedronate—osteoporosis	0.000266	0.00283	CcSEcCtD
Pentazocine—Insomnia—Ibandronate—osteoporosis	0.000265	0.00282	CcSEcCtD
Pentazocine—Chills—Zoledronate—osteoporosis	0.000265	0.00282	CcSEcCtD
Pentazocine—Paraesthesia—Ibandronate—osteoporosis	0.000264	0.0028	CcSEcCtD
Pentazocine—Constipation—Estropipate—osteoporosis	0.000262	0.00279	CcSEcCtD
Pentazocine—Hypersensitivity—Etidronic acid—osteoporosis	0.000261	0.00277	CcSEcCtD
Pentazocine—Loss of consciousness—Risedronate—osteoporosis	0.000261	0.00277	CcSEcCtD
Pentazocine—Insomnia—Calcitriol—osteoporosis	0.00026	0.00277	CcSEcCtD
Pentazocine—Agitation—Pamidronate—osteoporosis	0.000259	0.00276	CcSEcCtD
Pentazocine—Constipation—Alendronate—osteoporosis	0.000258	0.00274	CcSEcCtD
Pentazocine—Hypertension—Risedronate—osteoporosis	0.000256	0.00272	CcSEcCtD
Pentazocine—Somnolence—Calcitriol—osteoporosis	0.000255	0.00272	CcSEcCtD
Pentazocine—Decreased appetite—Ibandronate—osteoporosis	0.000255	0.00272	CcSEcCtD
Pentazocine—Syncope—Pamidronate—osteoporosis	0.000253	0.00269	CcSEcCtD
Pentazocine—Dysgeusia—Zoledronate—osteoporosis	0.000252	0.00268	CcSEcCtD
Pentazocine—Constipation—Ibandronate—osteoporosis	0.000251	0.00267	CcSEcCtD
Pentazocine—Pruritus—Etidronic acid—osteoporosis	0.00025	0.00266	CcSEcCtD
Pentazocine—Decreased appetite—Calcitriol—osteoporosis	0.00025	0.00266	CcSEcCtD
Pentazocine—Feeling abnormal—Alendronate—osteoporosis	0.000248	0.00264	CcSEcCtD
Pentazocine—Loss of consciousness—Pamidronate—osteoporosis	0.000248	0.00264	CcSEcCtD
Pentazocine—Muscle spasms—Zoledronate—osteoporosis	0.000247	0.00263	CcSEcCtD
Pentazocine—Dry mouth—Risedronate—osteoporosis	0.000247	0.00263	CcSEcCtD
Pentazocine—Constipation—Calcitriol—osteoporosis	0.000246	0.00261	CcSEcCtD
Pentazocine—Hypertension—Pamidronate—osteoporosis	0.000243	0.00259	CcSEcCtD
Pentazocine—Dysgeusia—Conjugated Estrogens—osteoporosis	0.000243	0.00258	CcSEcCtD
Pentazocine—Vision blurred—Zoledronate—osteoporosis	0.000243	0.00258	CcSEcCtD
Pentazocine—Diarrhoea—Etidronic acid—osteoporosis	0.000242	0.00258	CcSEcCtD
Pentazocine—Feeling abnormal—Ibandronate—osteoporosis	0.000242	0.00257	CcSEcCtD
Pentazocine—Tremor—Zoledronate—osteoporosis	0.000241	0.00257	CcSEcCtD
Pentazocine—Muscle spasms—Conjugated Estrogens—osteoporosis	0.000238	0.00254	CcSEcCtD
Pentazocine—Shock—Risedronate—osteoporosis	0.000238	0.00253	CcSEcCtD
Pentazocine—Agitation—Zoledronate—osteoporosis	0.000237	0.00252	CcSEcCtD
Pentazocine—Vision blurred—Conjugated Estrogens—osteoporosis	0.000234	0.00249	CcSEcCtD
Pentazocine—Confusional state—Pamidronate—osteoporosis	0.000232	0.00247	CcSEcCtD
Pentazocine—Vertigo—Zoledronate—osteoporosis	0.000231	0.00246	CcSEcCtD
Pentazocine—Syncope—Zoledronate—osteoporosis	0.000231	0.00246	CcSEcCtD
Pentazocine—Anaphylactic shock—Pamidronate—osteoporosis	0.00023	0.00245	CcSEcCtD
Pentazocine—Shock—Pamidronate—osteoporosis	0.000226	0.00241	CcSEcCtD
Pentazocine—Loss of consciousness—Zoledronate—osteoporosis	0.000226	0.00241	CcSEcCtD
Pentazocine—Hypersensitivity—Estropipate—osteoporosis	0.000226	0.0024	CcSEcCtD
Pentazocine—Vomiting—Etidronic acid—osteoporosis	0.000225	0.00239	CcSEcCtD
Pentazocine—Tachycardia—Pamidronate—osteoporosis	0.000224	0.00239	CcSEcCtD
Pentazocine—Dermatitis—Etidronic acid—osteoporosis	0.000223	0.00237	CcSEcCtD
Pentazocine—Vertigo—Conjugated Estrogens—osteoporosis	0.000223	0.00237	CcSEcCtD
Pentazocine—Hyperhidrosis—Pamidronate—osteoporosis	0.000222	0.00237	CcSEcCtD
Pentazocine—Syncope—Conjugated Estrogens—osteoporosis	0.000222	0.00236	CcSEcCtD
Pentazocine—Hypertension—Zoledronate—osteoporosis	0.000222	0.00236	CcSEcCtD
Pentazocine—Hypersensitivity—Alendronate—osteoporosis	0.000222	0.00236	CcSEcCtD
Pentazocine—Headache—Etidronic acid—osteoporosis	0.000222	0.00236	CcSEcCtD
Pentazocine—Asthenia—Estropipate—osteoporosis	0.00022	0.00234	CcSEcCtD
Pentazocine—Visual impairment—Estradiol—osteoporosis	0.00022	0.00234	CcSEcCtD
Pentazocine—Anorexia—Pamidronate—osteoporosis	0.000219	0.00233	CcSEcCtD
Pentazocine—Insomnia—Risedronate—osteoporosis	0.000219	0.00233	CcSEcCtD
Pentazocine—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000218	0.00232	CcSEcCtD
Pentazocine—Paraesthesia—Risedronate—osteoporosis	0.000217	0.00231	CcSEcCtD
Pentazocine—Pruritus—Estropipate—osteoporosis	0.000217	0.0023	CcSEcCtD
Pentazocine—Asthenia—Alendronate—osteoporosis	0.000216	0.0023	CcSEcCtD
Pentazocine—Hypersensitivity—Ibandronate—osteoporosis	0.000216	0.0023	CcSEcCtD
Pentazocine—EBP—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000216	0.0142	CbGpPWpGaD
Pentazocine—Dyspnoea—Risedronate—osteoporosis	0.000216	0.00229	CcSEcCtD
Pentazocine—Erythema multiforme—Estradiol—osteoporosis	0.000215	0.00229	CcSEcCtD
Pentazocine—Hypotension—Pamidronate—osteoporosis	0.000215	0.00229	CcSEcCtD
Pentazocine—Dry mouth—Zoledronate—osteoporosis	0.000214	0.00228	CcSEcCtD
Pentazocine—Pruritus—Alendronate—osteoporosis	0.000213	0.00227	CcSEcCtD
Pentazocine—Tinnitus—Estradiol—osteoporosis	0.000212	0.00226	CcSEcCtD
Pentazocine—Constipation—Ethinyl Estradiol—osteoporosis	0.000212	0.00226	CcSEcCtD
Pentazocine—Confusional state—Zoledronate—osteoporosis	0.000212	0.00225	CcSEcCtD
Pentazocine—Hypersensitivity—Calcitriol—osteoporosis	0.000212	0.00225	CcSEcCtD
Pentazocine—Flushing—Estradiol—osteoporosis	0.000211	0.00225	CcSEcCtD
Pentazocine—Asthenia—Ibandronate—osteoporosis	0.000211	0.00224	CcSEcCtD
Pentazocine—Nausea—Etidronic acid—osteoporosis	0.00021	0.00224	CcSEcCtD
Pentazocine—Anaphylactic shock—Zoledronate—osteoporosis	0.00021	0.00224	CcSEcCtD
Pentazocine—Diarrhoea—Estropipate—osteoporosis	0.000209	0.00223	CcSEcCtD
Pentazocine—Insomnia—Pamidronate—osteoporosis	0.000208	0.00221	CcSEcCtD
Pentazocine—Pruritus—Ibandronate—osteoporosis	0.000208	0.00221	CcSEcCtD
Pentazocine—Constipation—Risedronate—osteoporosis	0.000207	0.0022	CcSEcCtD
Pentazocine—Shock—Zoledronate—osteoporosis	0.000207	0.0022	CcSEcCtD
Pentazocine—Paraesthesia—Pamidronate—osteoporosis	0.000206	0.0022	CcSEcCtD
Pentazocine—Diarrhoea—Alendronate—osteoporosis	0.000206	0.00219	CcSEcCtD
Pentazocine—Asthenia—Calcitriol—osteoporosis	0.000206	0.00219	CcSEcCtD
Pentazocine—Dyspnoea—Pamidronate—osteoporosis	0.000205	0.00218	CcSEcCtD
Pentazocine—Tachycardia—Zoledronate—osteoporosis	0.000205	0.00218	CcSEcCtD
Pentazocine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000204	0.00218	CcSEcCtD
Pentazocine—Chills—Estradiol—osteoporosis	0.000204	0.00218	CcSEcCtD
Pentazocine—Somnolence—Pamidronate—osteoporosis	0.000204	0.00218	CcSEcCtD
Pentazocine—Pruritus—Calcitriol—osteoporosis	0.000203	0.00216	CcSEcCtD
Pentazocine—Hyperhidrosis—Zoledronate—osteoporosis	0.000203	0.00216	CcSEcCtD
Pentazocine—Diarrhoea—Raloxifene—osteoporosis	0.000203	0.00216	CcSEcCtD
Pentazocine—Dizziness—Estropipate—osteoporosis	0.000202	0.00215	CcSEcCtD
Pentazocine—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000202	0.00215	CcSEcCtD
Pentazocine—Diarrhoea—Ibandronate—osteoporosis	0.000201	0.00214	CcSEcCtD
Pentazocine—Anorexia—Zoledronate—osteoporosis	0.0002	0.00213	CcSEcCtD
Pentazocine—Decreased appetite—Pamidronate—osteoporosis	0.0002	0.00213	CcSEcCtD
Pentazocine—Dizziness—Alendronate—osteoporosis	0.000199	0.00212	CcSEcCtD
Pentazocine—Shock—Conjugated Estrogens—osteoporosis	0.000199	0.00212	CcSEcCtD
Pentazocine—Tachycardia—Conjugated Estrogens—osteoporosis	0.000197	0.0021	CcSEcCtD
Pentazocine—Constipation—Pamidronate—osteoporosis	0.000197	0.00209	CcSEcCtD
Pentazocine—Diarrhoea—Calcitriol—osteoporosis	0.000197	0.00209	CcSEcCtD
Pentazocine—Hypotension—Zoledronate—osteoporosis	0.000196	0.00209	CcSEcCtD
Pentazocine—Dizziness—Raloxifene—osteoporosis	0.000196	0.00209	CcSEcCtD
Pentazocine—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000196	0.00208	CcSEcCtD
Pentazocine—Vomiting—Estropipate—osteoporosis	0.000195	0.00207	CcSEcCtD
Pentazocine—Dysgeusia—Estradiol—osteoporosis	0.000194	0.00207	CcSEcCtD
Pentazocine—Dizziness—Ibandronate—osteoporosis	0.000194	0.00207	CcSEcCtD
Pentazocine—Dermatitis—Estropipate—osteoporosis	0.000193	0.00205	CcSEcCtD
Pentazocine—Anorexia—Conjugated Estrogens—osteoporosis	0.000193	0.00205	CcSEcCtD
Pentazocine—Headache—Estropipate—osteoporosis	0.000192	0.00204	CcSEcCtD
Pentazocine—Vomiting—Alendronate—osteoporosis	0.000192	0.00204	CcSEcCtD
Pentazocine—Muscle spasms—Estradiol—osteoporosis	0.000191	0.00203	CcSEcCtD
Pentazocine—Insomnia—Zoledronate—osteoporosis	0.00019	0.00202	CcSEcCtD
Pentazocine—Dermatitis—Alendronate—osteoporosis	0.00019	0.00202	CcSEcCtD
Pentazocine—Feeling abnormal—Pamidronate—osteoporosis	0.000189	0.00202	CcSEcCtD
Pentazocine—Hypotension—Conjugated Estrogens—osteoporosis	0.000189	0.00201	CcSEcCtD
Pentazocine—Headache—Alendronate—osteoporosis	0.000189	0.00201	CcSEcCtD
Pentazocine—Paraesthesia—Zoledronate—osteoporosis	0.000189	0.00201	CcSEcCtD
Pentazocine—OPRM1—IL4-mediated signaling events—COL1A1—osteoporosis	0.000189	0.0124	CbGpPWpGaD
Pentazocine—Vomiting—Raloxifene—osteoporosis	0.000189	0.00201	CcSEcCtD
Pentazocine—Dyspnoea—Zoledronate—osteoporosis	0.000187	0.00199	CcSEcCtD
Pentazocine—Dermatitis—Raloxifene—osteoporosis	0.000187	0.00199	CcSEcCtD
Pentazocine—Somnolence—Zoledronate—osteoporosis	0.000187	0.00199	CcSEcCtD
Pentazocine—Vomiting—Ibandronate—osteoporosis	0.000187	0.00199	CcSEcCtD
Pentazocine—Tremor—Estradiol—osteoporosis	0.000186	0.00198	CcSEcCtD
Pentazocine—Headache—Raloxifene—osteoporosis	0.000186	0.00198	CcSEcCtD
Pentazocine—Dermatitis—Ibandronate—osteoporosis	0.000185	0.00197	CcSEcCtD
Pentazocine—Headache—Ibandronate—osteoporosis	0.000184	0.00196	CcSEcCtD
Pentazocine—Insomnia—Conjugated Estrogens—osteoporosis	0.000183	0.00195	CcSEcCtD
Pentazocine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000183	0.00195	CcSEcCtD
Pentazocine—Vomiting—Calcitriol—osteoporosis	0.000183	0.00194	CcSEcCtD
Pentazocine—Decreased appetite—Zoledronate—osteoporosis	0.000183	0.00194	CcSEcCtD
Pentazocine—Agitation—Estradiol—osteoporosis	0.000182	0.00194	CcSEcCtD
Pentazocine—Nausea—Estropipate—osteoporosis	0.000182	0.00193	CcSEcCtD
Pentazocine—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000182	0.00193	CcSEcCtD
Pentazocine—Dermatitis—Calcitriol—osteoporosis	0.000181	0.00193	CcSEcCtD
Pentazocine—OPRM1—G-protein activation—POMC—osteoporosis	0.00018	0.0119	CbGpPWpGaD
Pentazocine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.00018	0.00192	CcSEcCtD
Pentazocine—Headache—Calcitriol—osteoporosis	0.00018	0.00192	CcSEcCtD
Pentazocine—Somnolence—Conjugated Estrogens—osteoporosis	0.00018	0.00191	CcSEcCtD
Pentazocine—Constipation—Zoledronate—osteoporosis	0.00018	0.00191	CcSEcCtD
Pentazocine—Nausea—Alendronate—osteoporosis	0.000179	0.00191	CcSEcCtD
Pentazocine—Hypersensitivity—Risedronate—osteoporosis	0.000178	0.0019	CcSEcCtD
Pentazocine—Vertigo—Estradiol—osteoporosis	0.000178	0.0019	CcSEcCtD
Pentazocine—Asthenia—Ethinyl Estradiol—osteoporosis	0.000178	0.00189	CcSEcCtD
Pentazocine—Syncope—Estradiol—osteoporosis	0.000178	0.00189	CcSEcCtD
Pentazocine—Nausea—Raloxifene—osteoporosis	0.000176	0.00187	CcSEcCtD
Pentazocine—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000176	0.00187	CcSEcCtD
Pentazocine—Pruritus—Ethinyl Estradiol—osteoporosis	0.000176	0.00187	CcSEcCtD
Pentazocine—Nausea—Ibandronate—osteoporosis	0.000174	0.00186	CcSEcCtD
Pentazocine—Loss of consciousness—Estradiol—osteoporosis	0.000174	0.00185	CcSEcCtD
Pentazocine—Asthenia—Risedronate—osteoporosis	0.000174	0.00185	CcSEcCtD
Pentazocine—Feeling abnormal—Zoledronate—osteoporosis	0.000173	0.00184	CcSEcCtD
Pentazocine—OPRM1—TCR Signaling Pathway—NFATC1—osteoporosis	0.000173	0.0114	CbGpPWpGaD
Pentazocine—Constipation—Conjugated Estrogens—osteoporosis	0.000173	0.00184	CcSEcCtD
Pentazocine—EBP—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000172	0.0114	CbGpPWpGaD
Pentazocine—Hypertension—Estradiol—osteoporosis	0.000171	0.00182	CcSEcCtD
Pentazocine—Pruritus—Risedronate—osteoporosis	0.000171	0.00182	CcSEcCtD
Pentazocine—Nausea—Calcitriol—osteoporosis	0.000171	0.00182	CcSEcCtD
Pentazocine—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.00017	0.00181	CcSEcCtD
Pentazocine—Hypersensitivity—Pamidronate—osteoporosis	0.000169	0.0018	CcSEcCtD
Pentazocine—Diarrhoea—Risedronate—osteoporosis	0.000166	0.00176	CcSEcCtD
Pentazocine—Dry mouth—Estradiol—osteoporosis	0.000165	0.00176	CcSEcCtD
Pentazocine—Asthenia—Pamidronate—osteoporosis	0.000165	0.00176	CcSEcCtD
Pentazocine—Dizziness—Ethinyl Estradiol—osteoporosis	0.000164	0.00175	CcSEcCtD
Pentazocine—Confusional state—Estradiol—osteoporosis	0.000163	0.00174	CcSEcCtD
Pentazocine—Pruritus—Pamidronate—osteoporosis	0.000163	0.00173	CcSEcCtD
Pentazocine—Anaphylactic shock—Estradiol—osteoporosis	0.000162	0.00172	CcSEcCtD
Pentazocine—Dizziness—Risedronate—osteoporosis	0.00016	0.0017	CcSEcCtD
Pentazocine—Shock—Estradiol—osteoporosis	0.000159	0.00169	CcSEcCtD
Pentazocine—Tachycardia—Estradiol—osteoporosis	0.000158	0.00168	CcSEcCtD
Pentazocine—Vomiting—Ethinyl Estradiol—osteoporosis	0.000158	0.00168	CcSEcCtD
Pentazocine—Diarrhoea—Pamidronate—osteoporosis	0.000157	0.00167	CcSEcCtD
Pentazocine—Hyperhidrosis—Estradiol—osteoporosis	0.000156	0.00167	CcSEcCtD
Pentazocine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000156	0.00166	CcSEcCtD
Pentazocine—Headache—Ethinyl Estradiol—osteoporosis	0.000155	0.00165	CcSEcCtD
Pentazocine—Hypersensitivity—Zoledronate—osteoporosis	0.000155	0.00165	CcSEcCtD
Pentazocine—Vomiting—Risedronate—osteoporosis	0.000154	0.00164	CcSEcCtD
Pentazocine—Dermatitis—Risedronate—osteoporosis	0.000152	0.00162	CcSEcCtD
Pentazocine—Dizziness—Pamidronate—osteoporosis	0.000152	0.00162	CcSEcCtD
Pentazocine—Headache—Risedronate—osteoporosis	0.000152	0.00161	CcSEcCtD
Pentazocine—Asthenia—Zoledronate—osteoporosis	0.000151	0.0016	CcSEcCtD
Pentazocine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000149	0.00159	CcSEcCtD
Pentazocine—Pruritus—Zoledronate—osteoporosis	0.000149	0.00158	CcSEcCtD
Pentazocine—Nausea—Ethinyl Estradiol—osteoporosis	0.000147	0.00157	CcSEcCtD
Pentazocine—EBP—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000147	0.00966	CbGpPWpGaD
Pentazocine—Insomnia—Estradiol—osteoporosis	0.000146	0.00156	CcSEcCtD
Pentazocine—Vomiting—Pamidronate—osteoporosis	0.000146	0.00156	CcSEcCtD
Pentazocine—Paraesthesia—Estradiol—osteoporosis	0.000145	0.00155	CcSEcCtD
Pentazocine—Asthenia—Conjugated Estrogens—osteoporosis	0.000145	0.00154	CcSEcCtD
Pentazocine—Dermatitis—Pamidronate—osteoporosis	0.000145	0.00154	CcSEcCtD
Pentazocine—Dyspnoea—Estradiol—osteoporosis	0.000144	0.00154	CcSEcCtD
Pentazocine—Headache—Pamidronate—osteoporosis	0.000144	0.00153	CcSEcCtD
Pentazocine—Somnolence—Estradiol—osteoporosis	0.000144	0.00153	CcSEcCtD
Pentazocine—Diarrhoea—Zoledronate—osteoporosis	0.000144	0.00153	CcSEcCtD
Pentazocine—Nausea—Risedronate—osteoporosis	0.000144	0.00153	CcSEcCtD
Pentazocine—Pruritus—Conjugated Estrogens—osteoporosis	0.000143	0.00152	CcSEcCtD
Pentazocine—Decreased appetite—Estradiol—osteoporosis	0.000141	0.0015	CcSEcCtD
Pentazocine—Dizziness—Zoledronate—osteoporosis	0.000139	0.00148	CcSEcCtD
Pentazocine—Constipation—Estradiol—osteoporosis	0.000138	0.00147	CcSEcCtD
Pentazocine—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000138	0.00147	CcSEcCtD
Pentazocine—Nausea—Pamidronate—osteoporosis	0.000137	0.00145	CcSEcCtD
Pentazocine—EBP—Metabolism—PKM—osteoporosis	0.000134	0.00881	CbGpPWpGaD
Pentazocine—EBP—Metabolism—FDPS—osteoporosis	0.000134	0.00881	CbGpPWpGaD
Pentazocine—Dizziness—Conjugated Estrogens—osteoporosis	0.000134	0.00142	CcSEcCtD
Pentazocine—Vomiting—Zoledronate—osteoporosis	0.000134	0.00142	CcSEcCtD
Pentazocine—Feeling abnormal—Estradiol—osteoporosis	0.000133	0.00142	CcSEcCtD
Pentazocine—Dermatitis—Zoledronate—osteoporosis	0.000132	0.00141	CcSEcCtD
Pentazocine—Headache—Zoledronate—osteoporosis	0.000132	0.0014	CcSEcCtD
Pentazocine—OPRD1—GPCR ligand binding—CALCR—osteoporosis	0.00013	0.00858	CbGpPWpGaD
Pentazocine—OPRD1—GPCR ligand binding—PTH1R—osteoporosis	0.00013	0.00858	CbGpPWpGaD
Pentazocine—Vomiting—Conjugated Estrogens—osteoporosis	0.000129	0.00137	CcSEcCtD
Pentazocine—Dermatitis—Conjugated Estrogens—osteoporosis	0.000127	0.00136	CcSEcCtD
Pentazocine—EBP—Metabolism—GPD2—osteoporosis	0.000127	0.00836	CbGpPWpGaD
Pentazocine—EBP—Metabolism—PGLS—osteoporosis	0.000127	0.00836	CbGpPWpGaD
Pentazocine—Headache—Conjugated Estrogens—osteoporosis	0.000127	0.00135	CcSEcCtD
Pentazocine—Nausea—Zoledronate—osteoporosis	0.000125	0.00133	CcSEcCtD
Pentazocine—Nausea—Conjugated Estrogens—osteoporosis	0.00012	0.00128	CcSEcCtD
Pentazocine—Hypersensitivity—Estradiol—osteoporosis	0.000119	0.00127	CcSEcCtD
Pentazocine—Asthenia—Estradiol—osteoporosis	0.000116	0.00124	CcSEcCtD
Pentazocine—EBP—Metabolism—ATIC—osteoporosis	0.000116	0.00764	CbGpPWpGaD
Pentazocine—EBP—Metabolism—PNP—osteoporosis	0.000116	0.00764	CbGpPWpGaD
Pentazocine—Pruritus—Estradiol—osteoporosis	0.000115	0.00122	CcSEcCtD
Pentazocine—OPRK1—GPCR ligand binding—PTH1R—osteoporosis	0.000114	0.00753	CbGpPWpGaD
Pentazocine—OPRK1—GPCR ligand binding—CALCR—osteoporosis	0.000114	0.00753	CbGpPWpGaD
Pentazocine—Diarrhoea—Estradiol—osteoporosis	0.000111	0.00118	CcSEcCtD
Pentazocine—OPRM1—IL4-mediated signaling events—IRS2—osteoporosis	0.00011	0.00728	CbGpPWpGaD
Pentazocine—OPRD1—G alpha (i) signalling events—CNR2—osteoporosis	0.00011	0.00726	CbGpPWpGaD
Pentazocine—Dizziness—Estradiol—osteoporosis	0.000107	0.00114	CcSEcCtD
Pentazocine—Vomiting—Estradiol—osteoporosis	0.000103	0.0011	CcSEcCtD
Pentazocine—OPRD1—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000102	0.00673	CbGpPWpGaD
Pentazocine—Dermatitis—Estradiol—osteoporosis	0.000102	0.00109	CcSEcCtD
Pentazocine—OPRM1—Opioid Signalling—ADCY5—osteoporosis	0.000102	0.00671	CbGpPWpGaD
Pentazocine—Headache—Estradiol—osteoporosis	0.000101	0.00108	CcSEcCtD
Pentazocine—EBP—Metabolism—CA2—osteoporosis	9.86e-05	0.0065	CbGpPWpGaD
Pentazocine—EBP—Metabolism—OXCT1—osteoporosis	9.86e-05	0.0065	CbGpPWpGaD
Pentazocine—OPRK1—G alpha (i) signalling events—CNR2—osteoporosis	9.66e-05	0.00636	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—CALCR—osteoporosis	9.65e-05	0.00636	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—PTH1R—osteoporosis	9.65e-05	0.00636	CbGpPWpGaD
Pentazocine—OPRM1—IL4-mediated signaling events—IRS1—osteoporosis	9.64e-05	0.00635	CbGpPWpGaD
Pentazocine—Nausea—Estradiol—osteoporosis	9.61e-05	0.00102	CcSEcCtD
Pentazocine—EBP—Metabolism—MGLL—osteoporosis	9.61e-05	0.00633	CbGpPWpGaD
Pentazocine—EBP—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	9.06e-05	0.00597	CbGpPWpGaD
Pentazocine—OPRK1—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	8.96e-05	0.00591	CbGpPWpGaD
Pentazocine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	8.76e-05	0.00577	CbGpPWpGaD
Pentazocine—EBP—Metabolism—IDH2—osteoporosis	8.17e-05	0.00538	CbGpPWpGaD
Pentazocine—OPRM1—G alpha (i) signalling events—CNR2—osteoporosis	8.16e-05	0.00538	CbGpPWpGaD
Pentazocine—EBP—Metabolism—CYP27A1—osteoporosis	7.68e-05	0.00506	CbGpPWpGaD
Pentazocine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	7.68e-05	0.00506	CbGpPWpGaD
Pentazocine—OPRM1—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	7.57e-05	0.00499	CbGpPWpGaD
Pentazocine—OPRM1—Opioid Signalling—POMC—osteoporosis	7.49e-05	0.00494	CbGpPWpGaD
Pentazocine—EBP—Metabolism—ACP5—osteoporosis	7.47e-05	0.00492	CbGpPWpGaD
Pentazocine—EBP—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	7.38e-05	0.00486	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—PTH1R—osteoporosis	7.36e-05	0.00485	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—CALCR—osteoporosis	7.36e-05	0.00485	CbGpPWpGaD
Pentazocine—EBP—Metabolism—TPI1—osteoporosis	6.95e-05	0.00458	CbGpPWpGaD
Pentazocine—OPRD1—GPCR ligand binding—PTH—osteoporosis	6.84e-05	0.00451	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—PTH1R—osteoporosis	6.68e-05	0.0044	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CALCR—osteoporosis	6.68e-05	0.0044	CbGpPWpGaD
Pentazocine—OPRD1—GPCR ligand binding—CNR2—osteoporosis	6.67e-05	0.00439	CbGpPWpGaD
Pentazocine—EBP—Metabolism—P4HB—osteoporosis	6.53e-05	0.0043	CbGpPWpGaD
Pentazocine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	6.49e-05	0.00428	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—PTH1R—osteoporosis	6.45e-05	0.00425	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—CALCR—osteoporosis	6.45e-05	0.00425	CbGpPWpGaD
Pentazocine—EBP—Metabolism—GAPDH—osteoporosis	6.41e-05	0.00422	CbGpPWpGaD
Pentazocine—OPRD1—GPCR ligand binding—WNT1—osteoporosis	6.27e-05	0.00413	CbGpPWpGaD
Pentazocine—EBP—Metabolism—RAP1A—osteoporosis	6.24e-05	0.00411	CbGpPWpGaD
Pentazocine—OPRK1—GPCR ligand binding—PTH—osteoporosis	6e-05	0.00395	CbGpPWpGaD
Pentazocine—OPRD1—G alpha (i) signalling events—ADCY5—osteoporosis	5.86e-05	0.00386	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CALCR—osteoporosis	5.86e-05	0.00386	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—PTH1R—osteoporosis	5.86e-05	0.00386	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—MGLL—osteoporosis	5.85e-05	0.00385	CbGpPWpGaD
Pentazocine—OPRK1—GPCR ligand binding—CNR2—osteoporosis	5.85e-05	0.00385	CbGpPWpGaD
Pentazocine—OPRD1—GPCR ligand binding—PTHLH—osteoporosis	5.67e-05	0.00374	CbGpPWpGaD
Pentazocine—OPRK1—GPCR ligand binding—WNT1—osteoporosis	5.5e-05	0.00362	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—CALCR—osteoporosis	5.45e-05	0.00359	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—PTH1R—osteoporosis	5.45e-05	0.00359	CbGpPWpGaD
Pentazocine—EBP—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.45e-05	0.00359	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—MGLL—osteoporosis	5.31e-05	0.0035	CbGpPWpGaD
Pentazocine—OPRK1—G alpha (i) signalling events—ADCY5—osteoporosis	5.14e-05	0.00339	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—MGLL—osteoporosis	5.13e-05	0.00338	CbGpPWpGaD
Pentazocine—OPRD1—Peptide ligand-binding receptors—POMC—osteoporosis	5.11e-05	0.00337	CbGpPWpGaD
Pentazocine—OPRM1—TCR Signaling Pathway—IL1B—osteoporosis	5.11e-05	0.00337	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—PTH—osteoporosis	5.07e-05	0.00334	CbGpPWpGaD
Pentazocine—EBP—Metabolism—ENO1—osteoporosis	5.05e-05	0.00333	CbGpPWpGaD
Pentazocine—OPRD1—GPCR ligand binding—CALCA—osteoporosis	4.99e-05	0.00329	CbGpPWpGaD
Pentazocine—EBP—Metabolism—PSMA2—osteoporosis	4.97e-05	0.00328	CbGpPWpGaD
Pentazocine—EBP—Metabolism—PSMA5—osteoporosis	4.97e-05	0.00328	CbGpPWpGaD
Pentazocine—OPRK1—GPCR ligand binding—PTHLH—osteoporosis	4.97e-05	0.00328	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CALCR—osteoporosis	4.95e-05	0.00326	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—PTH1R—osteoporosis	4.95e-05	0.00326	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—CNR2—osteoporosis	4.94e-05	0.00326	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—MGLL—osteoporosis	4.66e-05	0.00307	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—WNT1—osteoporosis	4.65e-05	0.00306	CbGpPWpGaD
Pentazocine—OPRK1—Peptide ligand-binding receptors—POMC—osteoporosis	4.48e-05	0.00295	CbGpPWpGaD
Pentazocine—OPRK1—GPCR ligand binding—CALCA—osteoporosis	4.38e-05	0.00288	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—SOST—osteoporosis	4.37e-05	0.00288	CbGpPWpGaD
Pentazocine—OPRM1—G alpha (i) signalling events—ADCY5—osteoporosis	4.35e-05	0.00286	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—MGLL—osteoporosis	4.33e-05	0.00286	CbGpPWpGaD
Pentazocine—OPRD1—G alpha (i) signalling events—POMC—osteoporosis	4.31e-05	0.00284	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—PTHLH—osteoporosis	4.2e-05	0.00277	CbGpPWpGaD
Pentazocine—EBP—Metabolism—CYP19A1—osteoporosis	4.04e-05	0.00266	CbGpPWpGaD
Pentazocine—OPRM1—TCR Signaling Pathway—TGFB1—osteoporosis	3.97e-05	0.00262	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PTH1R—osteoporosis	3.95e-05	0.0026	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CALCR—osteoporosis	3.95e-05	0.0026	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—MGLL—osteoporosis	3.94e-05	0.00259	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—PTH—osteoporosis	3.87e-05	0.00255	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—SOST—osteoporosis	3.83e-05	0.00252	CbGpPWpGaD
Pentazocine—OPRM1—Peptide ligand-binding receptors—POMC—osteoporosis	3.79e-05	0.0025	CbGpPWpGaD
Pentazocine—OPRK1—G alpha (i) signalling events—POMC—osteoporosis	3.78e-05	0.00249	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—CNR2—osteoporosis	3.77e-05	0.00248	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—CALCA—osteoporosis	3.7e-05	0.00244	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—PTH—osteoporosis	3.51e-05	0.00231	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PTH1R—osteoporosis	3.46e-05	0.00228	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CALCR—osteoporosis	3.46e-05	0.00228	CbGpPWpGaD
Pentazocine—OPRD1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	3.43e-05	0.00226	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CNR2—osteoporosis	3.42e-05	0.00225	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—PTH—osteoporosis	3.39e-05	0.00223	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—CNR2—osteoporosis	3.3e-05	0.00218	CbGpPWpGaD
Pentazocine—EBP—Metabolism—ADCY5—osteoporosis	3.3e-05	0.00217	CbGpPWpGaD
Pentazocine—EBP—Metabolism—GPX1—osteoporosis	3.29e-05	0.00217	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—SOST—osteoporosis	3.24e-05	0.00213	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—WNT1—osteoporosis	3.22e-05	0.00212	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—PTHLH—osteoporosis	3.2e-05	0.00211	CbGpPWpGaD
Pentazocine—OPRM1—G alpha (i) signalling events—POMC—osteoporosis	3.2e-05	0.00211	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—MGLL—osteoporosis	3.14e-05	0.00207	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—PTH—osteoporosis	3.08e-05	0.00203	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—LRP5—osteoporosis	3.06e-05	0.00202	CbGpPWpGaD
Pentazocine—EBP—Metabolism—MTHFR—osteoporosis	3.03e-05	0.002	CbGpPWpGaD
Pentazocine—OPRK1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	3.01e-05	0.00198	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CNR2—osteoporosis	3e-05	0.00198	CbGpPWpGaD
Pentazocine—OPRM1—TCR Signaling Pathway—IL6—osteoporosis	2.99e-05	0.00197	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—LRP6—osteoporosis	2.93e-05	0.00193	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PTH1R—osteoporosis	2.93e-05	0.00193	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CALCR—osteoporosis	2.93e-05	0.00193	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—PTHLH—osteoporosis	2.91e-05	0.00192	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—PTH—osteoporosis	2.87e-05	0.00189	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—WNT1—osteoporosis	2.82e-05	0.00186	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—CALCA—osteoporosis	2.82e-05	0.00186	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—PTHLH—osteoporosis	2.81e-05	0.00185	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—CNR2—osteoporosis	2.79e-05	0.00184	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—MGLL—osteoporosis	2.75e-05	0.00181	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—LRP5—osteoporosis	2.68e-05	0.00177	CbGpPWpGaD
Pentazocine—OPRD1—GPCR ligand binding—POMC—osteoporosis	2.61e-05	0.00172	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—PTH—osteoporosis	2.6e-05	0.00171	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—LRP6—osteoporosis	2.57e-05	0.00169	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CALCA—osteoporosis	2.56e-05	0.00169	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—PTHLH—osteoporosis	2.55e-05	0.00168	CbGpPWpGaD
Pentazocine—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	2.54e-05	0.00167	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CNR2—osteoporosis	2.54e-05	0.00167	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—CALCA—osteoporosis	2.47e-05	0.00163	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—TLN1—osteoporosis	2.47e-05	0.00163	CbGpPWpGaD
Pentazocine—EBP—Metabolism—POMC—osteoporosis	2.43e-05	0.0016	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—WNT1—osteoporosis	2.38e-05	0.00157	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—PTHLH—osteoporosis	2.37e-05	0.00156	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—MGLL—osteoporosis	2.32e-05	0.00153	CbGpPWpGaD
Pentazocine—OPRK1—GPCR ligand binding—POMC—osteoporosis	2.29e-05	0.00151	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—LRP5—osteoporosis	2.27e-05	0.0015	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CALCA—osteoporosis	2.25e-05	0.00148	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—LRP6—osteoporosis	2.17e-05	0.00143	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—TLN1—osteoporosis	2.17e-05	0.00143	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—PTHLH—osteoporosis	2.16e-05	0.00142	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—P4HB—osteoporosis	2.13e-05	0.00141	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—CALCA—osteoporosis	2.09e-05	0.00138	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PTH—osteoporosis	2.07e-05	0.00137	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—RAP1A—osteoporosis	2.04e-05	0.00134	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CNR2—osteoporosis	2.02e-05	0.00133	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—ADCY5—osteoporosis	2.01e-05	0.00132	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—NFATC1—osteoporosis	1.99e-05	0.00131	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—DKK1—osteoporosis	1.97e-05	0.0013	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—POMC—osteoporosis	1.94e-05	0.00128	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—WNT1—osteoporosis	1.9e-05	0.00125	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CALCA—osteoporosis	1.9e-05	0.00125	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—P4HB—osteoporosis	1.87e-05	0.00123	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—FGA—osteoporosis	1.85e-05	0.00122	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—TLN1—osteoporosis	1.83e-05	0.00121	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—ADCY5—osteoporosis	1.82e-05	0.0012	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PTH—osteoporosis	1.82e-05	0.0012	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—RAP1A—osteoporosis	1.79e-05	0.00118	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CNR2—osteoporosis	1.77e-05	0.00117	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—ADCY5—osteoporosis	1.76e-05	0.00116	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—NFATC1—osteoporosis	1.74e-05	0.00115	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—DKK1—osteoporosis	1.73e-05	0.00114	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—BMP2—osteoporosis	1.72e-05	0.00113	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PTHLH—osteoporosis	1.72e-05	0.00113	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—FGB—osteoporosis	1.68e-05	0.00111	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—WNT1—osteoporosis	1.67e-05	0.0011	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PSMA2—osteoporosis	1.62e-05	0.00107	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PSMA5—osteoporosis	1.62e-05	0.00107	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—FGA—osteoporosis	1.62e-05	0.00107	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—ADCY5—osteoporosis	1.6e-05	0.00105	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—P4HB—osteoporosis	1.58e-05	0.00104	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PTH—osteoporosis	1.54e-05	0.00101	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CALCA—osteoporosis	1.51e-05	0.000997	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—RAP1A—osteoporosis	1.51e-05	0.000995	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PTHLH—osteoporosis	1.51e-05	0.000993	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—BMP2—osteoporosis	1.51e-05	0.000993	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CNR2—osteoporosis	1.5e-05	0.000987	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—ADCY5—osteoporosis	1.49e-05	0.00098	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—POMC—osteoporosis	1.48e-05	0.000972	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—FGB—osteoporosis	1.47e-05	0.000972	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—NFATC1—osteoporosis	1.47e-05	0.000971	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—DKK1—osteoporosis	1.46e-05	0.000963	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PSMA2—osteoporosis	1.42e-05	0.000938	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PSMA5—osteoporosis	1.42e-05	0.000938	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—WNT1—osteoporosis	1.41e-05	0.000928	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—KL—osteoporosis	1.37e-05	0.000905	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—FGA—osteoporosis	1.37e-05	0.000903	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—ADCY5—osteoporosis	1.35e-05	0.00089	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—POMC—osteoporosis	1.34e-05	0.000883	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CALCA—osteoporosis	1.33e-05	0.000874	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—IL6R—osteoporosis	1.31e-05	0.000861	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—POMC—osteoporosis	1.29e-05	0.000853	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PTHLH—osteoporosis	1.27e-05	0.000839	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—BMP2—osteoporosis	1.27e-05	0.000839	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—FGB—osteoporosis	1.25e-05	0.000821	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—KL—osteoporosis	1.2e-05	0.000794	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PSMA2—osteoporosis	1.2e-05	0.000793	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PSMA5—osteoporosis	1.2e-05	0.000793	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—POMC—osteoporosis	1.18e-05	0.000774	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—IL6R—osteoporosis	1.15e-05	0.000755	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CALCA—osteoporosis	1.12e-05	0.000739	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—POMC—osteoporosis	1.09e-05	0.000721	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—ADCY5—osteoporosis	1.08e-05	0.000709	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—SPP1—osteoporosis	1.04e-05	0.000686	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—KL—osteoporosis	1.02e-05	0.000671	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—POMC—osteoporosis	9.93e-06	0.000654	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—IL6R—osteoporosis	9.69e-06	0.000638	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—ADCY5—osteoporosis	9.44e-06	0.000622	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IRS2—osteoporosis	9.42e-06	0.000621	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—LEP—osteoporosis	9.22e-06	0.000607	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—SPP1—osteoporosis	9.13e-06	0.000602	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—ESR1—osteoporosis	8.8e-06	0.00058	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IRS2—osteoporosis	8.26e-06	0.000544	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IRS1—osteoporosis	8.22e-06	0.000542	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—LEP—osteoporosis	8.08e-06	0.000533	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—ADCY5—osteoporosis	7.98e-06	0.000526	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—POMC—osteoporosis	7.92e-06	0.000522	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IL6R—osteoporosis	7.72e-06	0.000509	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—SPP1—osteoporosis	7.72e-06	0.000509	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—ESR1—osteoporosis	7.72e-06	0.000508	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IGF1—osteoporosis	7.62e-06	0.000502	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IRS1—osteoporosis	7.21e-06	0.000475	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IRS2—osteoporosis	6.98e-06	0.00046	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—POMC—osteoporosis	6.94e-06	0.000457	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—LEP—osteoporosis	6.83e-06	0.00045	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IL6R—osteoporosis	6.77e-06	0.000446	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IGF1—osteoporosis	6.68e-06	0.00044	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—ESR1—osteoporosis	6.52e-06	0.00043	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IRS1—osteoporosis	6.09e-06	0.000401	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—POMC—osteoporosis	5.87e-06	0.000387	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—IL6—osteoporosis	5.82e-06	0.000384	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IL6R—osteoporosis	5.72e-06	0.000377	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IGF1—osteoporosis	5.64e-06	0.000372	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—IL6—osteoporosis	5.11e-06	0.000336	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—MYC—osteoporosis	4.58e-06	0.000302	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—TGFB1—osteoporosis	4.57e-06	0.000301	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—IL6—osteoporosis	4.32e-06	0.000284	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—MYC—osteoporosis	4.01e-06	0.000264	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—TGFB1—osteoporosis	4e-06	0.000264	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IL6—osteoporosis	3.44e-06	0.000227	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—MYC—osteoporosis	3.39e-06	0.000223	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—TGFB1—osteoporosis	3.38e-06	0.000223	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IL6—osteoporosis	3.02e-06	0.000199	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IL6—osteoporosis	2.55e-06	0.000168	CbGpPWpGaD
